Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Sep 15.

Published in final edited form as: Int J Pharm. 2012 May 23;434(1-2):306–314. doi: 10.1016/j.ijpharm.2012.05.028

Fig.4 — Inhibition of Bcrp1 by m-TOR inhibitors: Intracellular accumulation of Bcrp1 substrate [³H]abacavir (ABC) in the absence and presence of increasing concentrations of everolimus (A) and temsirolimus (B). Values are expressed as (the percentage of control) Mean±S.D., n=3. (*, ** and *** represents p<0.05, p<0.01 and p<0.001 respectively).

Fig.4 — Inhibition of Bcrp1 by m-TOR inhibitors: Intracellular accumulation of Bcrp1 substrate [³H]abacavir (ABC) in the absence and presence of increasing concentrations of everolimus (A) and temsirolimus (B). Values are expressed as (the percentage of control) Mean±S.D., n=3. (*, ** and *** represents p<0.05, p<0.01 and p<0.001 respectively).